This is the second enduring activity derived from the live virtual event, MSGERC Town Hall: Challenging Infective Fungal Infections held on August 19, 2022. This activity, part of the Medical Mycology: Closing Gaps in Care initiative, has an expanded focus on therapeutic options, pharmacologic optimization, limitations of existing regimens, and emerging pharmacologic approaches. We will address these topics through 3 challenging clinical scenarios: a pulmonary infection in a post-lung-transplant patient; an acute myelogenous leukemia (AML) patient post chemotherapy with skin lesions, and a 51-year-old woman presenting with headaches and mental status changes. We hope that you find these cases helpful in your efforts to improve outcomes for patients with challenging invasive fungal infections.
Release Date: 11/15/2022
Expiration Date: 11/14/2023
Estimated Time to Complete the Activity: 1.25 hrs
Media: Interactive, text-based activity
Upon completing this activity, the participant should be better able to:
Primary audience: This activity is directed to infectious disease physicians, critical care physicians, hospitalists, surgeons, pathologists/clinical microbiologists, hematologists/oncologists, pharmacists, pediatric infectious disease specialists, transplant specialists, and other healthcare providers responsible for the management of invasive fungal infections.
Secondary audience: Primary care providers, GI, dermatology, and rheumatology specialists who work in the endemic areas or who see patients receiving biologics who are at risk for endemic mycoses.
In support of improving patient care, this activity has been planned and implemented by the Postgraduate Institute for Medicine (PIM); Terranova Medica, LLC; and the Mycoses Study Group Education and Research Consortium (MSGERC). Postgraduate Institute for Medicine is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
The Postgraduate Institute for Medicine designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Postgraduate Institute for Medicine designates this continuing education activity for 1.25 contact hours (0.125 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number –JA4008162-9999-22-402-H01-P
Type of Activity: Knowledge
Postgraduate Institute for Medicine (PIM) requires faculty, planners, and others in control of educational content to disclose all their financial relationships with ineligible companies. All identified conflicts of interest (COI) are thoroughly vetted and mitigated according to PIM policy. PIM is committed to providing its learners with high quality accredited continuing education activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.
The faculty reported the following relevant financial relationships with ineligible entities related to the educational content of this CE activity. All potential conflicts have been mitigated.
Luis Ostrosky-Zeichner, MD, FACP, FIDSA, FSHEA, FECMM, CMQ
RESEARCH SUPPORT: Astellas, Gilead, Pfizer, Pulmocide, Scynexis
CONSULTANT: Cidara, F2G, Appili Therapeutics, Merck & Co, Inc
SPEAKER: Pfizer, Gilead, F2G
George R. Thompson III, MD
RESEARCH SUPPORT: Cidara, Amplyx, Pfizer, F2G, Mayne Pharmaceuticals, Merck & Co, Inc
CONSULTANT: Cidara, Amplyx, Pfizer, F2G, Mayne Pharmaceuticals
James S. Lewis, II, PharmD, FIDSA
CONSULANT: Merck & Co., Inc; Cidara Therapeutics; SeLux Diagnostics
Lisa A. Tushla, PhD, H(ASCP) of Terranova Medica, LLC discloses research support from Bristol Myers Squibb and Novartis. The MSGERC and PIM planners have nothing to disclose.
There are no fees for participating and receiving CME/CE credit for this activity. During the accreditation period, participants must read the learning objectives and faculty disclosures and study the educational activity.
If you wish to receive acknowledgment for completing this activity, please follow the steps below:
For Pharmacists: Upon completion of the online evaluation, your credit will be submitted to CPE Monitor. Pharmacists have up to thirty (30) days to complete the evaluation and claim credit. Please check your NABP account within thirty (30) days to make sure the credit has posted.
Internet
To participate, you will need access to a computer (either MAC or PC), tablet, or smart phone, with a Chrome (version 22.0.1229.94 or greater) web browser, Firefox (version 3.6 or greater) web browser or an Internet Explorer (version 8.0 or greater) web browser, JavaScript enabled, connected to the Internet (high speed connection preferred).
Terranova Medica, LLC, and PIM are committed to protecting the privacy of those who choose to participate in activities on funguscme.org. This information below describes our security policies for safeguarding personal information as well as the rationale for collection and use of personal information.
Security/safeguarding personal information
This website has physical and procedural safeguards in place to prevent unauthorized access to personal information used to access this website.
Collection and use of personal information
Terranova Medica, LLC, and PIM do not transfer, sell, or share personal information with outside parties. We will not disclose the information unless required in a legal proceeding.
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the US Food and Drug Administration (FDA). The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
There is no charge for this activity.
Jointly provided by Postgraduate Institute for Medicine; Terranova Medica, LLC; and the Mycoses Study Group Education & Research Consortium.
This activity is supported by an independent educational grant from F2G.
For further information, contact Tom Davis by telephone (877-276-4523), or by email (tdavis@terranovamedica.com).
If you have any questions regarding the CME/CE certification for this activity, please contact Postgraduate Institute for Medicine at: inquiries@pimed.com or (303) 799-1930.
Copyright © 2022 PIM, MSGERC, and Terranova Medica.
